Key facts
- This page summarizes Herbert Raymond McMaster's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2021, 16:07.
Herbert Raymond McMaster - 26 Aug 2021 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)
- Reporting relationship
- Director
- Issuer ticker
- NRXP
- Reported as of
- 26 Aug 2021
- Net transaction value
- -$23,141
- SEC form
- 4
- Accepted by SEC
- 02 Nov 2021, 16:07:26 UTC
- Prior SEC filing
- 22 Jun 2021
- Next SEC filing
- 21 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Herbert R. McMaster
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Herbert Raymond McMaster filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 02 Nov 2021.
Change
- Previous filing in this sequence was filed on 22 Jun 2021.
- Current net transaction value: -$23,141.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRXP
transaction
Common Stock
Options Exercise
- Transaction value
- $40,626
- Shares
- +18,300
- Change %
- Price
- $2.22*
- Shares after
- 18,300
- Date
- 26 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRXP
transaction
Derivative
Employee Stock Option (Right to buy)
Conversion of derivative security
- Transaction value
- $63,767
- Shares
- -28,724
- Change %
- -64%
- Price
- $2.22*
- Shares after
- 16,362
- Date
- 26 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,724
- Exercise price
- $2.22
- Footnotes
- F1
NRXP
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +10,424
- Change %
- Price
- $0.000000
- Shares after
- 10,424
- Date
- 26 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,424
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The options are fully vested.
Footnote F2
Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.